MAP2K1 P124S

CI-VAR-00003271Explore in graph →NP_002746.1:p.Pro124SerNM_002755.3:c.370C>TClinVar 375981 CIViC 82 rs1057519732

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
MAP2K1 P124S	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	accepted	EID12986 MAP2K1 P124S was shown to constitutively activate ERK1/2 phosphorylation in the absence of serum in transiently transfected HEK293T cells (Fig 4a). In an NIH3T3 transformation assay (performed in trip… (full text at CIViC) PMID 22197931 · Nikolaev et al., 2011 · Open in CIViC	civic
Melanoma2
MAP2K1 P124S	Selumetinib	Predictive	D	Supports Resistance	3	accepted	EID12 A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells express… (full text at CIViC) PMID 19915144 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375981	Pathogenic	reviewed by expert panel	3	Noonan syndrome; Cardiofaciocutaneous syndrome 3; RASopathy; Spitz Melanocytoma; Metastatic melanoma; MAP2K1-related disorder	germline/somatic	7	Jan 10, 2025	clinvar